- Home
- ADUR vs PBYI Comparison
ADUR vs PBYI Comparison
Compare ADUR & PBYI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ADUR
- PBYI
- Stock Information
- Founded
- ADUR 2011
- PBYI 2010
- Country
- ADUR Canada
- PBYI United States
- Employees
- ADUR N/A
- PBYI N/A
- Industry
- ADUR
- PBYI Biotechnology: Pharmaceutical Preparations
- Sector
- ADUR
- PBYI Health Care
- Exchange
- ADUR NYSE
- PBYI Nasdaq
- Market Cap
- ADUR 144.2M
- PBYI 154.1M
- IPO Year
- ADUR N/A
- PBYI N/A
- Fundamental
- Price
- ADUR $5.13
- PBYI $3.01
- Analyst Decision
- ADUR Strong Buy
- PBYI Strong Buy
- Analyst Count
- ADUR 1
- PBYI 1
- Target Price
- ADUR $50.00
- PBYI $7.00
- AVG Volume (30 Days)
- ADUR 48.4K
- PBYI 372.2K
- Earning Date
- ADUR 01-01-0001
- PBYI 05-01-2025
- Dividend Yield
- ADUR N/A
- PBYI N/A
- EPS Growth
- ADUR N/A
- PBYI 37.78
- EPS
- ADUR N/A
- PBYI 0.62
- Revenue
- ADUR $213,431.00
- PBYI $230,468,000.00
- Revenue This Year
- ADUR N/A
- PBYI N/A
- Revenue Next Year
- ADUR N/A
- PBYI N/A
- P/E Ratio
- ADUR N/A
- PBYI $4.85
- Revenue Growth
- ADUR 23.94
- PBYI N/A
- 52 Week Low
- ADUR $1.34
- PBYI $2.23
- 52 Week High
- ADUR $7.00
- PBYI $6.06
- Technical
- Relative Strength Index (RSI)
- ADUR N/A
- PBYI 42.30
- Support Level
- ADUR N/A
- PBYI $3.14
- Resistance Level
- ADUR N/A
- PBYI $3.18
- Average True Range (ATR)
- ADUR 0.00
- PBYI 0.19
- MACD
- ADUR 0.00
- PBYI -0.06
- Stochastic Oscillator
- ADUR 0.00
- PBYI 17.81
About ADUR ADURO CLEAN TECHNOLOGIES INC
Aduro Clean Technologies Inc is a developer of patented water-based technologies to chemically recycle plastics and transform heavy crude and renewable oils into feedstocks and higher-value fuels. The company's technology activates unique properties of water in a chemistry platform that operates at relatively low temperatures and costs.
About PBYI Puma Biotechnology Inc
Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes innovative products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Also it develops alisertib. Alisertib is a selective, small-molecule inhibitor of aurora kinase A that is designed to disrupt mitosis leading to apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A.